Castro MSA, Méndez FS

Language: Spanish
References: 10
Page: 142-145
PDF size: 211.45 Kb.

ABSTRACT

Introduction: dermatomyositis positive for anti-melanoma differentiation- associated gene 5 (anti-MDA5 DM) is a rare disease, accounting for less than 2% of cases of idiopathic inflammatory myopathies (IIM), and primarily affecting the Asian population. The clinical presentation can be quite variable and challenging. It is characterized by the typical features of dermatomyositis, along with the development of deep cutaneous ulcers, which have a predilection for specific sites such as the dorsal part of the metacarpophalangeal or interphalangeal joints, knees, elbows, the digital pulp, and nail folds.
Case series: we present a series of six patients from a Mexican hospital with characteristic dermatological lesions associated with anti-MDA5 DM, with the aim of emphasizing the importance of knowing the cutaneous manifestations associated with this disease. These are associated with interstitial lung disease and have a high emotional component for patients due to the impact on their quality of life, primarily because of the ulcers they present.
Conclusions: identifying the most common lesions helps us make an early diagnosis and thus provide early treatment that could improve the survival of this disease.

REFERENCES

1. Nombel A, Fabien N y Coutant F, Dermatomyositis with antimda5antibodies: bioclinical features, pathogenesis and emergingtherapies, Front Immunol 2021; 12:773352.

2. DeWane ME, Waldman R y Lu J, Dermatomyositis: clinicalfeatures and pathogenesis, J Am Acad Dermatol 2020; 82(2):267-81.

3. Mammen AL, Allenbach Y, Stenzel W, Benveniste O y enmc239th Workshop Study Group, 239th enmc International Workshop:classification of dermatomyositis, Amsterdam, PaísesBajos, 14-16 de diciembre de 2018, Neuromuscul Disord nmd2020; 30(1):70-92.

4. Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W et al., Interstitiallung disease in anti-mda5 positive dermatomyositis, Clin RevAllergy Immunol 2021; 60(2):293-304.

5. Bolko L, Gitiaux C y Allenbach Y, Dermatomyositis: new antibody,new classification, Med Sci ms 2019; 35 Hors série 2:18-23.

6. Kurtzman DJB y Vleugels RA, Anti-melanoma differentiationassociatedgene 5 (mda5) dermatomyositis: a concise reviewwith an emphasis on distinctive clinical features, J Am AcadDermatol 2018; 78(4):776-85.

7. Romero-Bueno F, Díaz del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodríguez-Nieto MJ et al., Recommendationsfor the treatment of anti-melanoma differentiationassociatedgene 5-positive dermatomyositis-associated rapidlyprogressive interstitial lung disease, Semin Arthritis Rheum2020; 50(4):776-90.

8. Gupta R, Kumar S, Gow P, Hsien-Cheng L y Yen L, Anti-mda5-associated dermatomyositis, Intern Med J 2020; 50(4):484-7.

9. Vastarella M, Gallo L, Cantelli M, Nappa P y Fabbrocini G, Anundetected case of tinea capitis in an elderly woman affectedby dermatomyositis: how trichoscopy can guide to the right diagnosis,Skin Appendage Disord 2019; 5(3):186-8.

10. Hu H, Yang H, Liu Y y Yan B, Pathogenesis of anti-melanomadifferentiation-associated gene 5 antibody-positive dermatomyositis:a concise review with an emphasis on type i interferonsystem, Front Med 2022; 8:83311.